Prathamesh Patil
Krishna Institute of Medical Sciences Deemed University, Bharati Vidyapeeth Deemed University, Shivaji University
0000-0001-8628-5577
About
Prathamesh Patil is a pharmaceutical professional with an M.Pharm degree and is currently pursuing a Ph.D. in Pharmaceutical Sciences, specializing in cancer-targeted drug delivery systems. His doctoral research focuses on the development of advanced formulation strategies, including bio-ionic liquid-based micelles with surface functionalization for targeted anticancer therapy. He has over two years of industrial experience in formulation development and cancer diagnostics and has presented his research at international scientific conferences. His career vision is to contribute to innovation in novel drug delivery systems and advance into leadership roles in the global pharmaceutical industry.
Employment
-
Krishna Institute of Medical Sciences Deemed University PhD Scholar2024 - Present
Education
-
Krishna Institute of Medical Sciences Deemed University PhD2024 - 2027
-
Bharati Vidyapeeth Deemed University M.Pharm2020 - 2022
-
Shivaji University B. Pharm2016 - 2020
Projects & Funding
Projects & funding information is unavailable.
Publications (9)
- Optimization of Ionic Liquid Based NLC for Nose-To-Brain Delivery of Tetrabenazine Hydrochloride Save
- Thermoreversible Ionogel for Enhanced Nose-to-brain Delivery of Tetrabenazine Hydrochloride: Optimization by Central Composite Design and In Vitro Ex Vivo Evaluation Save
- Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer. Save
- Effect of circulating tumor cells in clinically stable patients on the conundrum of recurrence with cellular residual disease. Save
- Impact of circulating tumor DNA genomic mutations and circulating tumor cells biomarker duo on clinical concordance in localized, progressive, and metastatic disease. Save
- Measure of minimal residual burden on circulating tumor cells with over-expression of programmed death-ligand 1 as a dynamic biomarker in patients with colorectal cancer. Save
- HME-assisted formulation of taste-masked dispersible tablets of cefpodoxime proxetil and roxithromycin Save
- Abstract 7508: Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers Save
- Abstract 7509: Evaluation ofHER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer Save